Bioshares in its latest addition released today covered the annual Wilson HTM annual life sciences conference which aims to show case the 12 best listed life science companies in Australia in one day with analyst interviews with each company.
Acrux was one of those companies this year.
Acrux - Axiron, A Defining Asset:
Richard Treagus, CEO of Acrux, said Axiron (transdermally) delivered male testosterone) is a company defining asset for Acrux. Although 80% of the market is in the US, the Brazil and China markets are 'exploding'. Acrux could have done a deal for Axiron at the end of Phase II, which would have validated the program. However, larger drug deals are done in Phase III/NDA (new drug application) stage products.
Acrux is managing the supply of Axiron through its manufacturer, Orion Corporation in Finland, which has a lot of experience in making therapeutics hormone products. The Phase III results reported recently by Acrux has triggered strong interest from a variety of potential partner companies.
Add to My Watchlist
What is My Watchlist?
